News Athersys, Inc.

Equities

ATHXQ

US04744L2051

Market Closed - OTC Markets Other stock markets 03:47:30 2024-05-03 pm EDT			5-day change	1st Jan Change
0.0043 ^USD	+4.88%		-2.27%	-78.50%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 05	Athersys, Inc. Announces Board Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Athersys : Acquisition/Asset Disposal - Form 8-K	Apr. 05	PU
Athersys, Inc. Announces Board Changes	Apr. 05	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	Apr. 04	MT
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	Apr. 02	CI
Final DIP Financing Approved for Athersys, Inc.	Feb. 12	CI
Bidding Procedure Approved for Athersys, Inc.	Feb. 12	CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal	Jan. 17	MT
Interim DIP Financing Approved for Athersys, Inc.	Jan. 12	CI
Motion for Joint Administration Approved for Athersys, Inc.	Jan. 11	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	Jan. 10	MT
Motion for Asset Sale Filed by Athersys, Inc.	Jan. 05	CI
Motion for Joint Administration Filed by Athersys, Inc.	Jan. 05	CI
Athersys, Inc. Filed for Bankruptcy	Jan. 04	CI
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	Jan. 04	CI
Athersys, Inc. Announces Termination of Maia Hansen as Chief Operating Officer, Effective from December 31, 2023	Dec. 22	CI
Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023	Dec. 22	CI
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights	Nov. 17	AQ
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives	Nov. 17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Athersys, Inc.

Equities

ATHXQ

US04744L2051

Summary

Filters